Related Experiment Video
Updated: May 13, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Novel immunotherapies in GU malignancies
Alexandra Drakaki1, David F McDermott
1Beth Israel Deaconess Medical Center, 330 Brookline Ave, Rabb 430, Boston, MA, 02215, USA. adrakaki@bidmc.harvard.edu
Abstract:
Despite the development of several novel therapies in recent years, genitourinary (GU) malignancies remain associated with significant morbidity and mortality. An improved understanding of how the immune system responds to cancer has led to the clinical development of several targeted immunotherapies. Data from recent clinical trials suggests that these agents might improve the prognosis of patients with advanced GU malignancies. This review article will discuss the current state of immunotherapy and describe future directions in combination therapy and biomarker development for cancers of the kidney, bladder and prostate.
Insights
Genitourinary cancers are deadly, but new immunotherapies show promise. This review explores current treatments and future combination strategies for kidney, bladder, and prostate cancers.
Area of Science:
- Oncology
- Immunology
Background:
- Genitourinary (GU) malignancies contribute significantly to cancer morbidity and mortality.
- Recent advancements in understanding cancer immunology have spurred the development of targeted immunotherapies.
Purpose of the Study:
- To review the current landscape of immunotherapy for GU cancers.
- To discuss future directions, including combination therapies and biomarker development.
Main Methods:
- Literature review of recent clinical trials and research.
- Analysis of immunotherapy efficacy in advanced GU malignancies.
- Exploration of novel therapeutic strategies.
Main Results:
- Emerging data suggests immunotherapies can improve outcomes for advanced GU cancers.
- Targeted immunotherapies represent a significant advancement in GU oncology.
Conclusions:
- Immunotherapy holds considerable promise for improving patient prognosis in kidney, bladder, and prostate cancers.
- Future research should focus on optimizing combination therapies and identifying predictive biomarkers.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
